fashion -WSS

fashion

author：Wikipedia 2025-09-06 04:41:53 - browse：6699

STAT's Casey Ross (left) and Kimberly Powell, NVIDIA's vice president for healthcare at the STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by a single-mile marker: When will we get an AI-designed drug?

The answer remains, ambiguously, “the future,” but at STAT’s Breakthrough Summit leaders from NVIDIA and Google insisted that the impact of AI is visible today.

Kimberly Powell, vice president of healthcare for NVIDIA, pointed to an increase in investigational new drug applications filed with the Food and Drug Administration that cite AI, as well as an uptick in early-stage readouts from clinical trials, as evidence of progress. Some of the recent readouts, Powell said, show that what’s going into Phase 1 clinical trials is more successful.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Fed up with FDA, ALS advocates consider a take

WSS

House panel takes first step toward fixing drug shortages

David Liu startup to focus on CRISPR delivery

Covid’s new normal has set in amid another rise in cases

Why the quest to eradicate polio has stumbled

The struggle to figure out which patients 'deserve' Wegovy

Morphosys mixed study results for blood cancer drug

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Medicare proposal to cover medical devices draws a mixed reaction

House panel takes first step toward fixing drug shortages

Bright Health sells Medicare Advantage business to Molina

Information blocking fines are now fair game in health care

Hepatitis C has a cure — but many Americans still lack access to it

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Medicare proposal to cover medical devices draws a mixed reaction

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Novavax promises a turnaround & Lilly roils the obesity market

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Wikipedia

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

World's first CRISPR

A daunting task: navigating dual Medicare, Medicaid eligibility

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

NYU radiologists take on the challenge of expensive MRI machines

Senate bill would ban some hospital facility fees

focus

leisure time

hotspot

hotspot